[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ochsner Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":169},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,69,92,117,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632641","cold-and-compression-after-rotator-cuff-repair-rcr-100632641",false,"NCT07516327","Cold and Compression After Rotator Cuff Repair (RCR)","Cold and Compression After Rotator Cuff Repair or Arthroscopic Rotator Cuff Repair Pain Attenuation: A Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Aged 35 yr or older\n2. Patient of Drs. Michael Hartman (PI), Ian Elliott, Jay French, or Paul Phillips at Ochsner Kenner scheduled for arthroscopic rotator cuff repair\n3. Will receive outpatient physical therapy at OTW Driftwood for the entire post-op rehabilitation period\n4. English speaking\n5. Diagnosis of high-grade partial or full thickness rotator cuff tears\n\nExclusion Criteria:\n\n1. Chronic opioid use\n2. Opioid use within the last 3 months\n3. Diagnosis of inflammatory disease process (i.e., gout, rheumatoid arthritis, systematic lupus erythematosus...)\n4. Discharge to skilled nursing\n5. Cold intolerance related to diseases, like Raynaud's\n6. Significant vascular impairment in the affected region\n7. Current clinical signs of inflammatory phlebitis, venous ulcers, or cellulitis\n8. Significant risk factors or current clinical signs of embolism (e.g., pulmonary embolus, pulmonary edema, cerebral infarction, atrial fibrillation, endocarditis, myocardial infarction, or atheromatous embolic plaque)\n9. A condition in which increased venous or lymphatic return is not desired in the affected extremity (e.g., lymphedema after breast cancer or other local carcinoma and\u002For carcinoma metastasis in the affected extremity).\n10. Uncontrolled hypertension (physician discretion), cardiac failure, extreme low blood pressure, or decompensated cardiac insufficiency.\n11. Localized unstable skin condition (e.g., dermatitis, vein ligation, gangrene, or recent skin graft) in the affected region.\n12. Had recent toe surgery in the affected region\n13. Current clinical signs in the affected region of significant peripheral edema (e.g., deep vein thrombosis, chronic venous insufficiency, acute compartment syndrome, systemic venous hypertension, congestive heart failure, cirrhosis\u002Fliver failure, renal failure).\n14. An acute, unstable (untreated) fracture in the affected region.\n15. Any active local or systemic infection.\n16. Obtunded or with diabetes mellitus, multiple sclerosis, poor circulation, spinal cord injuries, and rheumatoid arthritis\n17. Areas of skin breakdown or damage (damaged or at-risk skin) producing uneven heat conduction across the skin (e.g., open wound, scar tissue, burn or skin graft). Any open wound must be dressed prior to use of the Polar Care Wave System.\n18. Presumptive evidence of congestive heart failure\n19. Pre-existing DVT condition\n20. Deep acute venal thrombosis (Phlebothrombosis)\n21. Episodes of pulmonary embolism\n22. Pulmonary edema\n23. Acute inflammation of the veins (Thrombophlebitis)\n24. Decompensated cardiac insufficiency\n25. Arterial dysregulation\n26. Erysipelas\n27. Carcinoma and carcinoma metastasis in the affected extremity\n28. Decompensated hypertonia\n29. Acute inflammatory skin diseases or infection\n30. Venous or arterial occlusive disease\n31. Medical situations where increased venous or lymphatic return is undesirable\n32. Poor peripheral circulation\n33. Severe arteriosclerosis, or active infection\n34. Known hematological dyscrasias that predispose to thrombosis (e.g., paroxysmal cold hemoglobinuria, cryoglobulinemia, sicklecell disease, serum cold agglutinins).\n35. Tissues inflamed as a result of recent injury or exacerbation of chronic inflammatory condition.\n36. Compromised local circulation or neurologic impairment (including paralysis or localized compromise due to multiple surgical procedures or diabetes) in the affected region.\n37. Cognition or communication impairments that prevent them from giving accurate and timely feedback.\n38. Cold allergy\n39. Cold agglutinin disorders like paroxysmal cold hemoglobinuria\n40. Buerger's disease\n41. Chilblains\n42. Cryoglobulinemia\n43. Sickle cell anemia\n44. Uncontrolled diabetes (physician discretion)\n45. Hypersensitivity to cold","ALL","35 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to compare pain score (Patient-Reported Outcomes Measurement Information System: PROMIS NRS Pain Subscale) between the control and cold\u002Fcompression groups pre-surgically, daily after surgery for 14 days, then weekly after surgery for 3 months, and at 6 months post-surgery.",[26],"High-grade Partial or Full Thickness Rotator Cuff Tears",[28,29,30,31,32],"Rotator Cuff","RCR","Cold Compression","Acute Pain","Post surgical pain","RECRUITING","2026-04-09",{"date":36,"type":37},"2026-04-14","ACTUAL",{"date":39,"type":37},"2026-03-01",{"date":41,"type":20},"2029-08-31",{"name":43,"class":44},"Ochsner Health System","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":24,"conditions":56,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100594725","cold-and-compression-post-tka-100594725","NCT07023185","Cold and Compression Post TKA","Cold and Compression After Total Knee Arthroplasty for Pain Attenuation: A Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Aged 50 yr or older\n2. Patient of Dr. Howard Hirsch or Dr. Vinod Dasa scheduled for total knee arthroplasty (knee replacement) at Ochsner Kenner\n3. Will receive outpatient physical therapy at OTW Driftwood for the entire post-op rehabilitation period\n4. English speaking\n5. Diagnosis of primary osteoarthritis\n\nExclusion Criteria:\n\n1. Chronic opioid use\n2. Opioid use within the last 3 months\n3. PCS score ≥ 30\n4. Diagnosis of inflammatory disease process (i.e., gout, rheumatoid arthritis, systematic lupus erythematosus...)\n5. Discharge to skilled nursing\n6. Cold intolerance related to diseases, like Raynaud's\n7. Significant vascular impairment in the affected region\n8. Current clinical signs of inflammatory phlebitis, venous ulcers, or cellulitis\n9. Significant risk factors or current clinical signs of embolism (e.g., pulmonary embolus, pulmonary edema, cerebral infarction, atrial fibrillation, endocarditis, myocardial infarction, or atheromatous embolic plaque)\n10. A condition in which increased venous or lymphatic return is not desired in the affected extremity (e.g., lymphedema after breast cancer or other local carcinoma and\u002For carcinoma metastasis in the affected extremity).\n11. Uncontrolled hypertension (physician discretion), cardiac failure, extreme low blood pressure, or decompensated cardiac insufficiency.\n12. Localized unstable skin condition (e.g., dermatitis, vein ligation, gangrene, or recent skin graft) in the affected region.\n13. Had recent toe surgery in the affected region\n14. Current clinical signs in the affected region of significant peripheral edema (e.g., deep vein thrombosis, chronic venous insufficiency, acute compartment syndrome, systemic venous hypertension, congestive heart failure, cirrhosis\u002Fliver failure, renal failure).\n15. An acute, unstable (untreated) fracture in the affected region.\n16. Any active local or systemic infection.\n17. Obtunded or with diabetes mellitus, multiple sclerosis, poor circulation, spinal cord injuries, and rheumatoid arthritis\n18. Areas of skin breakdown or damage (damaged or at-risk skin) producing uneven heat conduction across the skin (e.g., open wound, scar tissue, burn or skin graft). Any open wound must be dressed prior to use of the Polar Care Wave System.\n19. Presumptive evidence of congestive heart failure\n20. Pre-existing DVT condition\n21. Deep acute venal thrombosis (Phlebothrombosis)\n22. Episodes of pulmonary embolism\n23. Pulmonary edema\n24. Acute inflammation of the veins (Thrombophlebitis)\n25. Decompensated cardiac insufficiency\n26. Arterial dysregulation\n27. Erysipelas\n28. Carcinoma and carcinoma metastasis in the affected extremity\n29. Decompensated hypertonia\n30. Acute inflammatory skin diseases or infection\n31. Venous or arterial occlusive disease\n32. Medical situations where increased venous or lymphatic return is undesirable\n33. Poor peripheral circulation\n34. Severe arteriosclerosis, or active infection\n35. Known hematological dyscrasias that predispose to thrombosis (e.g., paroxysmal cold hemoglobinuria, cryoglobulinemia, sicklecell disease, serum cold agglutinins).\n36. Tissues inflamed as a result of recent injury or exacerbation of chronic inflammatory condition.\n37. Compromised local circulation or neurologic impairment (including paralysis or localized compromise due to multiple surgical procedures or diabetes) in the affected region.\n38. Cognition or communication impairments that prevent them from giving accurate and timely feedback.\n39. Cold allergy\n40. Cold agglutinin disorders like paroxysmal cold hemoglobinuria\n41. Buerger's disease\n42. Chilblains\n43. Cryoglobulinemia\n44. Sickle cell anemia\n45. Uncontrolled diabetes (physician discretion)\n46. Hypersensitivity to cold\n47. History of cold injury\n48. Severe cardiovascular disease, anesthetic skin, hypercoagulation disorders, poor circulation, extremities sensitive to pain, extremely low blood pressure that are incapacitated, decreased skin sensitivity, vein ligation or recent skin grafts, or pheochromocytoma.","50 Years",{"count":19,"type":20},[23],[57],"Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery",[59,60],"total knee replacement","primary osteoarthritis","2026-04-01",{"date":63,"type":37},"2026-04-02",{"date":65,"type":37},"2025-12-15",{"date":67,"type":20},"2028-06",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100610391","gait-after-tha-direct-anterior-vs-manual-posterior-vs-robotic-posterior-100610391","NCT07226973","Gait After THA: Direct Anterior vs Manual Posterior vs Robotic Posterior","A Prospective, Single-Blinded, Partially Randomized Three-Cohort Study Comparing Manual Direct Anterior and Manual Posterior Approaches to a Non-Randomized Robotic Posterior Cohort for Total Hip Arthroplasty Using Gait Analysis","Inclusion Criteria:\n\n* Adults aged \\>18 undergoing primary elective THA for osteoarthritis\n* BMI \\\u003C35\n* Ability to walk unassisted (cane, walker, wheelchair, ect) for \\> 150 feet preoperatively\n\nExclusion Criteria:\n\n* Previous hip surgery on the affected side\n* Neurological disorders affecting gait\n* Contraindication to either DAA or PA","18 Years",{"count":78,"type":20},48,[23],"The purpose of this study is to evaluate the gait biomechanics following THA on 3 groups of subjects undergoing DAA (manual) and PA (manual and robotic) surgical approaches.",[82],"Osteoarthritis (OA) of the Hip","2025-11-06",{"date":85,"type":37},"2025-11-12",{"date":87,"type":37},"2025-10-09",{"date":89,"type":20},"2027-11-15",{"name":43,"class":44},2,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100512554","90y-transarterial-radioembolization-versus-microwave-ablation-in-small-hepatocellular-carcinoma-with-hypoalbuminemia-100512554","NCT05953961","90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia","Randomized Study of Therapshere 90-Yittrium Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia","REALM","Inclusion Criteria:\n\n* HCC diagnosis according to the Liver Imaging - Reporting Data System (LI-RADS) Criteria as defined in the American Association for the Study of Liver Diseases 2018 HCC practice guidelines\n* Eastern Cooperative Oncology Group score 0 - 1\n* Child-Pugh A - B\n* Bilirubin \\\u003C 2.5 mg\u002FdL\n* Creatinine \\\u003C 2.0 mg\u002FdL\n* No prior liver-directed therapy or systemic therapy for HCC\n* Solitary, unresectable HCC ≤ 3cm\n* Albumin level \\\u003C 3.4 g\u002FdL at HCC diagnosis\n* Tumor anatomical location and angiosome amendable to MWA and 90Y\n\nExclusion Criteria:\n\n* Pregnant women\n* Concurrent malignancy",{"count":101,"type":20},50,[23],"This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA). The study will determine whether treatment with 90Y lowers the risk of disease progression within the first year after diagnosis. Participants will be randomized to receive either first cycle 90Y or MWA and then proceed with standard of care.",[105],"Carcinoma, Hepatocellular",[107,108],"Yttrium-90","Hypoalbuminemia","2025-07-30",{"date":111,"type":37},"2025-08-03",{"date":113,"type":37},"2023-08-08",{"date":115,"type":20},"2027-01",{"name":43,"class":44},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":124,"minAge":76,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":45},"100586836","remote-postpartum-blood-pressure-monitoring-and-cardiovascular-education-100586836","NCT06920563","Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education","Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education to Reduce Emergency Department Visits, Re-admissions and Adverse Cardiovascular Outcomes in Hypertensive Disorder of Pregnancy","Inclusion Criteria:\n\n1. Age of at least 18 years.\n2. Postpartum status.\n3. Experience new-onset hypertension during pregnancy.\n4. Enrollment in Connected MOM.\n5. Ability to provide informed consent.\n6. Establish medical care within the Ochsner System to facilitate data collection.\n\nExclusion Criteria:\n\n1. History of preeclampsia or gestational hypertension during previous pregnancy\n2. History of chronic hypertension\n3. History of coronary artery disease (myocardial infarction, coronary stent placement, coronary artery bypass grafting, spontaneous coronary artery dissection)\n4. History of ischemic CVA\n5. History of Congestive heart failure\n6. Renal dysfunction\n7. Liver dysfunction\n8. Left ventricular dysfunction\n9. Congenital heart disease\n10. Still birth at delivery","FEMALE",{"count":126,"type":20},296,[23],"The goal of this clinical trial is to learn if patient education and regular text reminders are a feasible intervention to engage patients and reduce post partum hypertension. The main questions it aims to answer are:\n\nIs a structured postpartum remote blood pressure monitoring intervention with education and individualized medication initiation\u002Fadjustment follow-up by televisit feasible? Does a structured program reduce the occurrence of postpartum hypertension, ED visits, hospital readmissions, and adverse outcomes?\n\nParticipants will:\n\nView an educational video on HDP post-delivery Receive 1-2 times daily text messages for 6 weeks postpartum Have their blood pressure medications adjusted to lower targets post partum",[130,131],"Pre-Eclampsia; Complicating Pregnancy","Gestational Hypertension","2025-04-01",{"date":134,"type":37},"2025-04-09",{"date":136,"type":37},"2025-03-17",{"date":138,"type":20},"2026-10-16",{"name":43,"class":44},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":45},"100563209","phase-4-colonoscopy-and-antiplatelet-therapy-trial-100563209","NCT06613191","Colonoscopy and Antiplatelet Therapy Trial","P2Y12 Inhibitor Versus Aspirin Monotherapy in Patients Undergoing Elective Screening and Surveillance Colonoscopy","CAPTT","Inclusion Criteria:\n\n1. Age ≥ 45 years\n2. Stable patients defined as having Angina CCS (Canadian Cardiovascular Society) class 1-3 and\u002For Heart Failure NYHA class 1-2 without a change in guideline directed anti-ischemic or heart failure medications within 30 days prior to randomization.\n3. Patients with cardiovascular disease defined as coronary artery disease, cerebrovascular disease or peripheral vascular disease taking DAPT (defined as aspirin plus a P2Y12 inhibitor). The decision to use DAPT in this patient will be made by the managing physician(s) before recruitment for this study. Consider replacing last statement with \"As directed by their physician prior to recruitment into this study\"\n4. Scheduled for elective screening or surveillance outpatient colonoscopy\n\nExclusion Criteria:\n\n1. Coronary intervention (PCI or CABG) less than 90 days prior to randomization\n2. ACS event in less than 90 days prior to randomization\n3. Transient ischemic attack (TIA) and\u002For stroke event in less than 90 days prior to randomization\n4. Acute limb ischemia and\u002For amputation in less than 90 days prior to randomization\n5. Post cardiac valve replacement (either percutaneous or surgical)\n6. High cardiovascular risk:\n\n   1. Patients with CCS class 4 angina\n   2. Hospitalized with ACS within 1 month prior to randomization\n   3. Patients undergoing PCI or CABG within the 3 months prior to randomization\n7. Patients on left ventricular assist device (LVAD) or post cardiac transplantation\n8. Patients with NYHA class 3 or 4 heart failure\n9. Any condition requiring treatment requires chronic use of an anticoagulant.\n10. Chronic kidney disease Stage 5 (with or without dialysis)\n11. Liver cirrhosis with platelet count \\< 50,000\u002F mm3 and\u002For INR \\>1.4\n12. Hematocrit \\< 30% and hemoglobin \\< 10 mg\u002FdL\n13. Emergent or inpatient Colonoscopy","45 Years",{"count":150,"type":20},100,[152],"PHASE4","Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \\[clopidogrel, prasugrel, or ticagrelor\\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.",[155,156],"Coronary Arterial Disease (CAD)","Peripheral Vascular Disease",[158,159],"Colonoscopy","Antiplatelet therapy","NOT_YET_RECRUITING","2024-09-23",{"date":163,"type":37},"2024-09-25",{"date":165,"type":20},"2024-10-01",{"date":167,"type":20},"2026-06-30",{"name":43,"class":44},""]